Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials

CONCLUSIONS: These findings suggest that hypertension is a distinctive adverse event associated with niraparib compared to other PARP inhibitors. Niraparib significantly increases the risk of hypertension that needs early recognition and management in clinical medication.PMID:38295607 | DOI:10.1016/j.ygyno.2024.01.012

Source: Gynecologic Oncology - January 31, 2024 Category: Cancer & Oncology Authors: Wei Chen Jiyi Xie Chen Gao Cong Zhang Zhiwen Fu Chen Shi Source Type: research